Biotechnology company developing therapies to extend healthy human lifespan by treating aging
Biotechnology company developing therapies to extend healthy human lifespan by treating aging. Its programs include cell replacement using iPSC-derived microglia and blood stem cells, tissue rejuvenation with small molecules, gene therapy and AI-designed proteins, and AI-enabled biological research. The company operates in-house cell manufacturing and automated laboratory infrastructure; its lead autophagy drug is in Phase 1.